KROS (Keros Therapeutics, Inc.) — Stock Analysis, Catalysts & AI Research

Keros Therapeutics, Inc.

$10.07

Health CareBiotechnology

The Read: 6% after its KER-065 Phase 2 trial initiation failed to inspire confidence, then dropped another 7.

Price

Overlays

Panel

KROS

Hover to view data

No Data

The Stats

Market Cap

N/A

Total outstanding shares value

Earnings Per Share (EPS)

N/A

Latest reported

Net Profit Margin

N/A

Net Income / Revenue

Revenue Growth (YoY)

N/A

Prior year same period

Debt / Equity

N/A

Leverage risk indicator

Dividend Yield

0.00%

Annualized Return

Free Cash Flow

N/A

No data

Keros Therapeutics, Inc.

$10.07

Health CareBiotechnology

The Read: 6% after its KER-065 Phase 2 trial initiation failed to inspire confidence, then dropped another 7.

Price

Overlays

Panel

KROS

Hover to view data

No Data

The Stats

Market Cap

N/A

Total outstanding shares value

Earnings Per Share (EPS)

N/A

Latest reported

Net Profit Margin

N/A

Net Income / Revenue

Revenue Growth (YoY)

N/A

Prior year same period

Debt / Equity

N/A

Leverage risk indicator

Dividend Yield

0.00%

Annualized Return

Free Cash Flow

N/A

No data

Create your free account to unlock active Expected Moves for KROS

Expected Moves

Keros Therapeutics, Inc.

The Stats

Market Cap

Earnings Per Share (EPS)

Net Profit Margin

Revenue Growth (YoY)

Debt / Equity

Dividend Yield

Free Cash Flow

Create your free account to unlock active Expected Moves for KROS

Expected Moves

Keros Therapeutics, Inc.

The Stats

Market Cap

Earnings Per Share (EPS)

Net Profit Margin

Revenue Growth (YoY)

Debt / Equity

Dividend Yield

Free Cash Flow